MAPK	O
Signaling	O
and	O
Inflammation	O
Link	O
Melanoma	O
Phenotype	O
Switching	O
to	O
Induction	O
of	O
CD73	O
during	O
Immunotherapy	O
.	O


Evolution	O
of	O
tumor	O
cell	O
phenotypes	O
promotes	O
heterogeneity	O
and	O
therapy	O
resistance	O
.	O


Here	O
we	O
found	O
that	O
induction	O
of	O
CD73	O
,	O
the	O
enzyme	O
that	O
generates	O
immunosuppressive	O
adenosine	O
,	O
is	O
linked	O
to	O
melanoma	O
phenotype	O
switching	O
.	O


Activating	O
MAPK	O
mutations	O
and	O
growth	O
factors	O
drove	O
CD73	O
expression	O
,	O
which	O
marked	O
both	O
nascent	O
and	O
full	O
activation	O
of	O
a	O
mesenchymal	O
-	O
like	O
melanoma	O
cell	O
state	O
program	O
.	O


Proinflammatory	O
cytokines	O
like	O
TNFalpha	O
cooperated	O
with	O
MAPK	O
signaling	O
through	O
the	O
c	O
-	O
Jun	O
/	O
AP	O
-	O
1	O
transcription	O
factor	O
complex	O
to	O
activate	O
CD73	O
transcription	O
by	O
binding	O
to	O
an	O
intronic	B-ENHANCER
enhancer	E-ENHANCER
.	O


In	O
a	O
mouse	O
model	O
of	O
T	O
-	O
cell	O
immunotherapy	O
,	O
CD73	O
was	O
induced	O
in	O
relapse	O
melanomas	O
,	O
which	O
acquired	O
a	O
mesenchymal	O
-	O
like	O
phenotype	O
.	O


We	O
also	O
detected	O
CD73	O
upregulation	O
in	O
melanoma	O
patients	O
progressing	O
under	O
adoptive	O
T	O
-	O
cell	O
transfer	O
or	O
immune	O
checkpoint	O
blockade	O
,	O
arguing	O
for	O
an	O
adaptive	O
resistance	O
mechanism	O
.	O


Our	O
work	O
substantiates	O
CD73	O
as	O
a	O
target	O
to	O
combine	O
with	O
current	O
immunotherapies	O
,	O
but	O
its	O
dynamic	O
regulation	O
suggests	O
limited	O
value	O
of	O
CD73	O
pretreatment	O
expression	O
as	O
a	O
biomarker	O
to	O
stratify	O
melanoma	O
patients	O
.	O


Cancer	O
Res	O
;	O
77	O
(	O
17	O
)	O
;	O
4697	O
-	O
709	O
.	O


2017	O
AACR	O
.	O
